Edition:
United Kingdom

STRATEC Biomedical AG (SBSG.DE)

SBSG.DE on Xetra

69.40EUR
20 Apr 2018
Change (% chg)

€0.90 (+1.31%)
Prev Close
€68.50
Open
€68.10
Day's High
€69.70
Day's Low
€68.10
Volume
11,062
Avg. Vol
7,938
52-wk High
€80.30
52-wk Low
€48.97

Latest Key Developments (Source: Significant Developments)

STRATEC Biomedical To Propose Increased Dividend Of EUR 0.80/Shr
Thursday, 19 Apr 2018 

April 19 (Reuters) - STRATEC Biomedical AG ::FY SALES ROSE 13.4 PERCENT TO 209.8 MILLION EUR.DIVIDEND 0.80 EURPER SHARE VERSUS 0.77 EURPER SHARE YEAR AGO.FY ADJUSTED EBIT RISES 10.1% TO EUR 35.5 MILLION IN 2017 (PREVIOUS YEAR: EUR 32.2 MILLION).ADJUSTED CONSOLIDATED EARNINGS 10.4% HIGHER IN 2017 AT EUR 27.9 MILLION.OUTLOOK 2018: FURTHER GROWTH FORECAST.EXPECTS ADJUSTED EBIT MARGIN FOR FISCAL 2018 IN LINE WITH PREVIOUS YEAR'S FIGURE OF AROUND 17%.OUTLOOK 2018: AT LEAST MID-SINGLE-DIGIT ORGANIC SALES GROWTH.EXPECTS TO GENERATE MOST OF SALES GROWTH PLANNED FOR 2018 IN SECOND HALF OF FINANCIAL YEAR.TO PROPOSE TRANSFORMATION OF STRATEC BIOMEDICAL INTO EUROPEAN COMPANY KNOWN AS STRATEC SE.  Full Article

STRATEC Biomedical To Modify Its Legal Form To That Of European Company
Thursday, 12 Apr 2018 

April 12 (Reuters) - STRATEC Biomedical AG ::INTENDS TO MODIFY ITS LEGAL FORM TO THAT OF A EUROPEAN COMPANY.AS PART OF THIS CHANGE, NAME SUPPLEMENT "BIOMEDICAL" WILL BE DROPPED IN FUTURE.  Full Article

Stratec Biomedical 9mth adj EBIT up at EUR 24.0 mln
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - STRATEC BIOMEDICAL AG ::9M SALES ROSE 19.6 PERCENT TO 151.1 MILLION EUR.‍OUTLOOK FOR 2017 FINANCIAL YEAR CONFIRMED​.‍ADJUSTED EBIT MARGIN OF 15.9% IN 9M|2017 (9M|2016: 14.6%)​.9MTH ADJUSTED EBIT GREW BY 30.4% FROM EUR 18.4 MILLION IN PREVIOUS YEAR TO EUR 24.0 MILLION IN 2017​.9MTH ‍ADJ CONSOLIDATED NET INCOME UP YEAR-ON-YEAR BY 22.1% TO EUR 18.6 MILLION.  Full Article

Stratec sees sales rising to 205-220 mln euros in 2017
Thursday, 21 Jul 2016 

Stratec Biomedical AG : Sees 2016 sales at eur 175 million to eur 182 million . Sees 2017 sales at eur 205 million to eur 220 million . Q2 (organic) sales +2.6% to eur 36.3 million (Q2/2015: eur 35.5 million) . Q2 saw recognition of non- recurring items, amounting to eur 1.4 million . Sales are expected to rise to between eur 205 million and eur 220 million, with a slight increase in ebit margin compared with 2016 . Q2 (organic) EBIT margin at 17.5% (Q2/2015: 17.3%) .2017 sales are expected to rise to between eur 205 million and eur 220 million, with a slight increase in ebit margin compared with 2016.  Full Article